Currently, the traditional approach to assess whether cancer patients benefit from anti‐PD‐1 includes the detection of programmed cell death ligand 1 (PD‐L1) expression, microsatellite instability, and tumor mutation burden (TMB) from tumor tissues [10, 11, 12]. The gene discussed is CD274; the disease is neoplasm.